Notch1-mediated tumor suppression in cervical cancer with the involvement of SST signaling and its application in enhanced SSTR-targeted therapeutics

Oncologist

Volumn 17, Issue 2, 2012, Pages 220-232

  Franko Tobin, Laura G ^a   Mackey, L Vienna ^a   Huang, Wei ^a   Song, Xiangwei ^a   Jin, Baofeng ^b   Luo, Jing ^a   Morris, Lynsie M ^a   Liu, Minqiu ^c   Fuselier, Joseph A ^a   Coy, David H ^a   Wu, Lizi ^b   Sun, Lichun ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c FUDAN UNIVERSITY   (China)

Author keywords

Cervical cancer; Notch1 signaling; Receptor targeted therapy; Sst signaling; Tumor suppression

Indexed keywords

CYCLIC AMP; CYTOTOXIC AGENT; CYTOTOXIC SOMATOSTATIN CONJUGATE; FORSKOLIN; G PROTEIN COUPLED RECEPTOR; HISTONE DEACETYLASE; MYC PROTEIN; NOTCH1 RECEPTOR; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P63; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; STAT3 PROTEIN; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; COLONY FORMING CELL; CONTROLLED STUDY; DRUG CONJUGATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; UTERINE CERVIX CANCER; WESTERN BLOTTING;

EID: 84863176401     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0269     Document Type: Article

References (58)

1. Wu L, Griffin JD. Modulation of Notch signaling by mastermind-like (MAML) transcriptional co-activators and their involvement in tumorigenesis. Semin Cancer Biol 2004;14:348-356.
2. Wu L, Aster JC, Blacklow SC et al. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat Genet 2000;26:484-489.
3. Kunnimalaiyaan M, Chen H. Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. The Oncologist 2007;12:535-542.
4. Allenspach EJ, Maillard I, Aster JC et al. Notch signaling in cancer. Cancer Biol Ther 2002;1:466-476.
5. Guan E, Wang J, Laborda J et al. T cell leukemia-associated human Notch/translocation-associated Notch homologue has I kappa B-like activity and physically interacts with nuclear factor-kappa B proteins in T cells. J Exp Med 1996;183:2025-2032.
6. Maillard I, Pear WS. Notch and cancer: Best to avoid the ups and downs. Cancer Cell 2003;3:203-205.
7. Weng AP, Aster JC. Multiple niches for Notch in cancer: Context is everything. Curr Opin Genet Dev 2004;14:48-54.
8. Dotto GP. Notch tumor suppressor function. Oncogene 2008;27:5115-5123.
9. Koch U, Radtke F. Notch and cancer:Adoubleedged sword. Cell Mol Life Sci 2007;64:2746-2762.
10. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood 2006;107:2223-2233.
11. Sjölund J, Manetopoulos C, Stockhausen MT et al. The Notch pathway in cancer: Differentiation gone awry. Eur J Cancer 2005;41:2620-2629.
12. Bolós V, Blanco M, Medina V et al. Notch signalling in cancer stem cells. Clin Transl Oncol 2009;11:11-19.
13. Wang Z, Li Y, Banerjee S et al. Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-K{green}B signaling pathways. J Cell Biochem 2010; 109:726-736.
14. Roy M, Pear WS, Aster JC. The multifaceted role of Notch in cancer. Curr Opin Genet Dev 2007; 17:52-59.
15. Proweller A, Tu L, Lepore JJ et al. Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Res 2006;66:7438-7444.
16. Kunnimalaiyaan M, Traeger K, Chen H. Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 2005;289:G636-G642.
17. Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M et al. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by Notch signaling. J Clin Endocrinol Metab 2005; 90:4350-4356.
18. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA et al. Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem 2006;281:39819-39830.
19. Weijzen S, Zlobin A, Braid M et al. HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. J Cell Physiol 2003;194:356-362.
20. Yao J, Duan L, Fan M et al. Notch1 induces cell cycle arrest and apoptosis in human cervical cancer cells: Involvement of nuclear factor kappa B inhibition. Int J Gynecol Cancer 2007;17:502-510.
21. Wang L, Qin H, Chen B et al. Overexpressed active Notch1 induces cell growth arrest of HeLa cervical carcinoma cells. Int J Gynecol Cancer 2007;17:1283-1292.
22. Talora C, Sgroi DC, Crum CP et al. Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev 2002;16:2252-2263.
23. Yu H, Zhao X, Huang S et al. Blocking Notch1 signaling by RNA interference can induce growth inhibition in HeLa cells. Int J Gynecol Cancer 2007;17:511-516.
24. Dueñas-Gonzàlez A, Lizano M, CandelariaMet al. Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer 2005;4: 38-61.
25. Malinowski DP. Multiple biomarkers in molecular oncology. I. Molecular diagnostics applications in cervical cancer detection. Expert Rev Mol Diagn 2007;7:117-131.
26. Perez-Plasencia C, Duenas-Gonzalez A, Alatorre-Tavera B. Second hit in cervical carcinogenesis process: Involvement of wnt/beta catenin pathway. Int Arch Med 2008;1:10-17.
27. Ramdass B, Maliekal TT, Lakshmi S et al. Coexpression of Notch1 and NF-K{green}B signaling pathway components in human cervical cancer progression. Gynecologic Oncol 2007;104:352-361.
28. Ma YY, Wei SJ, Lin YC et al. PIK3CA as an oncogene in cervical cancer. Oncogene 2000;19: 2739-2744.
29. Kulkarni S, Rader JS, Zhang F et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001;7:429-434.
30. Rincón-Arano H, Rosales R, Mora N et al. RRas promotes tumor growth of cervical epithelial cells. Cancer 2003;97:575-585.
31. Srivastava S, Ramdass B, Nagarajan S et al. Notch1 regulates the functional contribution of RhoC to cervical carcinoma progression. Br J Cancer 2010;102:196-205.
32. Zagouras P, Stifani S, Blaumueller CM et al. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc Natl Acad Sci U S A 1995;92:6414-6418.
33. Tewari KS, Taylor JA, Liao SY et al. Development and assessment of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model. Gynecol Oncol 2000;77:137-148.
34. Sun L, Zhan Q, Zhang W et al. Aberrant expression of Notch1 in cervical cancer. Chinese J Clin Oncol 2007;4:38-41.
35. Talora C, Cialfi S, Segatto O et al. Constitutively active Notch1 induces growth arrest of HPVpositive cervical cancer cells via separate signaling pathways. Exp Cell Res 2005;305:343-354.
36. Sun LC, Luo L, Mackey LV et al. Investigation of cancer cell lines for peptide receptor-targeted drug development. J Drug Target 2011;19: 719-730.
37. Xiao D, Wang J, Hampton LL et al. The human gastrin-releasing peptide receptor gene structure, its tissue expression and promoter. Gene 2001; 264:95-103.
38. Reubi JC, Läderach U, Waser B et al. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 2000;60:3105-3112.
39. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
40. Engel JB, Schally AV, Halmos G et al. Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. Endocr Relat Cancer 2005;12:999-1009.
41. Sun LC, Coy DH. Somatostatin receptortargeted anti-cancer therapy. Curr Drug Deliv 2011;8:2-10.
42. Sun L, Coy DH. Cytotoxic conjugates of peptide hormones for cancer chemotherapy. Drugs Future 2008;33:217-223.
43. Pyronnet S, Bousquet C, Najib S et al. Antitumor effects of somatostatin. Mol Cell Endocrinol 2008;286:230-237.
44. Calzavara E, Chiaramonte R, Cesana D et al. Reciprocal regulation of Notch and PI3K/Akt signalling in T-ALL cells in vitro. J Cell Biochem 2008;103:1405-1412.
45. Ghosh S, Choritz L, Geibel J et al. Somatostatin modulates PI3K-Akt, eNOS andNHEactivity in the ciliary epithelium. Mol Cell Endocrinol 2006; 253:63-75.
46. Reubi JC, Schaer JC, Laissue JA et al. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism 1996; 45(suppl 1):39-41.
47. Grozinsky-Glasberg S, Shimon I, Korbonits M et al. Somatostatin analogues in the control of neuroendocrine tumours: Efficacy and mechanisms. Endocr Relat Cancer 2008;15:701-720.
48. Panetta R, Patel YC. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci 1995;56:333-342.
49. Bellavia D, Mecarozzi M, Campese AF et al. Notch3 and the Notch3-upregulated RNA-binding protein HuD regulate Ikaros alternative splicing. EMBO J 2007;26:1670-1680.
50. Sun LC, Mackey LV, Luo J et al. Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice. Clin Med Oncol 2008;2:491-499.
51. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-198.
52. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006;17:1733-1742.
53. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R et al. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. The Oncologist 2007;12:942-951.
54. Loeken MR. Effects of mutation of the CREB binding site of the somatostatin promoter on cyclic AMP responsiveness in CV-1 cells. Gene Expr 1993;3:253-264.
55. Du ZY, Qin RY, Xia W et al. Gene transfer of somatostatin receptor type 2 by intratumoral injection inhibits established pancreatic carcinoma xenografts. World J Gastroenterol 2005;11:516-520.
56. Celinski SA, Fisher WE, Amaya F et al. Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts. J Surg Res 2003;115:41-47.
57. Chateauvieux S, Morceau F, Dicato M et al. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010;2010.pii: 479364. Epub 2010 Jul 29.
58. Stefan H, Feuerstein TJ. Novel anticonvulsant drugs. Pharmacol Ther 2007;113:165-183.